Get access

Targeting Efficiency and Biodistribution of Zoledronate Conjugated Docetaxel Loaded Pegylated PBCA Nanoparticles for Bone Metastasis

Authors

  • Kiran R. Chaudhari,

    1. TIFAC Centre of Relevance and Excellence in New Drug Delivery Systems, Shri G. H. Patel Pharmacy Building, Pharmacy Department, The Maharaja Sayajirao University of Baroda, Donor's Plaza, Fatehgunj, Vadodara-390002, India
    2. School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio-70211, Finland
    3. Department of Radiopharmaceuticals and Radiation Biology, Institute of Nuclear Medicine and Allied Sciences (INMAS), Brigadier S. K. Mazumdar Road, Delhi-110054, India
    Search for more papers by this author
  • Abhinesh Kumar,

    1. TIFAC Centre of Relevance and Excellence in New Drug Delivery Systems, Shri G. H. Patel Pharmacy Building, Pharmacy Department, The Maharaja Sayajirao University of Baroda, Donor's Plaza, Fatehgunj, Vadodara-390002, India
    Search for more papers by this author
  • Vinoth Kumar Megraj Khandelwal,

    1. School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio-70211, Finland
    2. Tumor Cell Invasion Laboratory, Consorzio Mario Negri Sud, Santa Maria Imbaro-66030, Italy
    Search for more papers by this author
  • Anil K. Mishra,

    1. Department of Radiopharmaceuticals and Radiation Biology, Institute of Nuclear Medicine and Allied Sciences (INMAS), Brigadier S. K. Mazumdar Road, Delhi-110054, India
    Search for more papers by this author
  • Jukka Monkkonen,

    1. School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio-70211, Finland
    Search for more papers by this author
  • Rayasa S. Ramachandra Murthy

    Corresponding author
    1. ISF College of Pharmacy, Firozpur G. T. Road, Moga-142001, Punjab, India
    • ISF College of Pharmacy, Firozpur G. T. Road, Moga-142001, Punjab, India.
    Search for more papers by this author

Abstract

In an attempt to improve tumor localization of docetaxel (DTX)-loaded nanoparticles (NPs), zoledronic acid (ZOL) is used as a ligand to target bone metastasis. DTX-loaded ZOL-conjugated polyethylene glycol (PEG)ylated polybutyl cyanoacrylate (PBCA) NPs are prepared using an anionic polymerization technique. PBCA-PEG-ZOL NPs are subjected to cytotoxic assay in both BO2 and MCF-7 cell lines. Cell cycle arrest and apoptosis induced by the PBCA-PEG-ZOL NPs are studied. Quantitative cellular uptake, NP uptake route characterization, confocal microscopy and IPP/ApppI levels are performed. PBCA-PEG-ZOL NPs show an enhanced cytotoxic effect in both BO2 as well as MCF-7 cell lines due to higher uptake following ZOL-mediated endocytosis. The molecular basis of apoptosis reveals the involvement of a cytoplasmic protein in activating the programmed cell death pathway. Route characterization studies reveal that PBCA-PEG-ZOL NPs uptake is not completely blocked even by using both inhibitors (genistein and phenyl arsinoxide) simultaneously, conferring that uptake is not entirely based upon clathrin or caveolae. PBCA-PEG-ZOL NPs showed 7 and 5.3 times increase in IPP and ApppI production, in comparison to ZOL treatment, and 138 times higher than the control group in MCF-7 cell line. In BO2 cell line, after treatment with NPs, IPP was 5.35 times higher than ZOL solution. No ApppI in BO2 cell line after treatment with NPs and ZOL solution was found. NP distribution in tumor infected bone is also significantly high in comparison to the normal bone at any time point. It is concluded that ZOL-conjugated NPs provide an efficient and targeted delivery of DTX, with synergistic effects. Thus, these NPs present a promising treatment in the near future, by actively targeting metastatic tumor.

Get access to the full text of this article

Ancillary